Linezolid resistance in Staphylococcus aureus:: Characterization and stability of resistant phenotype

被引:134
作者
Pillai, SK
Sakoulas, G
Wennersten, C
Eliopoulos, GM
Moellering, RC
Ferraro, MJ
Gold, HS
机构
[1] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1086/345368
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Linezolid is an important therapeutic option for treatment of infections caused by glycopeptide- and beta-lactam-resistant gram-positive organisms. Linezolid resistance is caused by mutations within the domain V region of the 23S ribosomal RNA (rRNA) gene, which is present in multiple copies in most bacteria. Among clinical Staphylococcus aureus isolates, there has been only 1 reported case of linezolid resistance. In the present study, this isolate was further characterized by determination of the number of mutant 23S rRNA copies, assessment of the stability of the resistant phenotype, and comparison of its growth characteristics with those of linezolid-susceptible S. aureus. All 5 copies of the 23S rRNA gene contained a G2576U mutation in the domain V region. After serial passage on antibiotic-free medium, the isolate maintained resistance to high concentrations of linezolid. Compared with 2 linezolid-susceptible S. aureus isolates, the linezolid-resistant S. aureus isolate demonstrated no significant differences in in vitro growth characteristics.
引用
收藏
页码:1603 / 1607
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 38 SAN DIEG CA US IN
[2]  
[Anonymous], 39 INT C ANT AG CHEM
[3]   Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes [J].
Aoki, H ;
Ke, LZ ;
Poppe, SM ;
Poel, TJ ;
Weaver, EA ;
Gadwood, RC ;
Thomas, RC ;
Shinabarger, DL ;
Ganoza, MC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1080-1085
[4]  
Brent, 1997, SHORT PROTOCOLS MOL
[5]   Oxazolidinone antibiotics [J].
Diekema, DJ ;
Jones, RN .
LANCET, 2001, 358 (9297) :1975-1982
[6]  
GOERING RV, 2001, 41 INT C ANT AG CHEM, P119
[7]   Nosocomial spread of linezolid-resistant, vancomycin-resistant enterococcus faecium [J].
Herrero, IA ;
Issa, NC ;
Patel, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (11) :867-869
[8]   In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis [J].
Kaatz, GW ;
Seo, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :799-801
[9]   Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center [J].
Kloss, P ;
Xiong, LQ ;
Shinabarger, DL ;
Mankin, AS .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 294 (01) :93-101
[10]   Whole genome sequencing of meticillin-resistant Staphylococcus aureus [J].
Kuroda, M ;
Ohta, T ;
Uchiyama, I ;
Baba, T ;
Yuzawa, H ;
Kobayashi, I ;
Cui, LZ ;
Oguchi, A ;
Aoki, K ;
Nagai, Y ;
Lian, JQ ;
Ito, T ;
Kanamori, M ;
Matsumaru, H ;
Maruyama, A ;
Murakami, H ;
Hosoyama, A ;
Mizutani-Ui, Y ;
Takahashi, NK ;
Sawano, T ;
Inoue, R ;
Kaito, C ;
Sekimizu, K ;
Hirakawa, H ;
Kuhara, S ;
Goto, S ;
Yabuzaki, J ;
Kanehisa, M ;
Yamashita, A ;
Oshima, K ;
Furuya, K ;
Yoshino, C ;
Shiba, T ;
Hattori, M ;
Ogasawara, N ;
Hayashi, H ;
Hiramatsu, K .
LANCET, 2001, 357 (9264) :1225-1240